Bal Pharma is currently trading at Rs. 92.90, up by 0.15 points or 0.16% from its previous closing of Rs. 92.75 on the BSE.
The scrip opened at Rs. 95.00 and has touched a high and low of Rs. 95.20 and Rs. 92.00 respectively. So far 6823 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 128.00 on 01-Jan-2018 and a 52 week low of Rs. 84.45 on 06-Feb-2018.
Last one week high and low of the scrip stood at Rs. 96.00 and Rs. 92.00 respectively. The current market cap of the company is Rs. 130.39 crore.
The promoters holding in the company stood at 44.57%, while Institutions and Non-Institutions held 0.13% and 55.30% respectively.
Bal Pharma has entered into collaboration with Akaal Pharma, Melbourne, Australia whereby both companies have launched a Joint Venture Company (JVC) - AB VET Pharma. The new joint venture will be completely funded by Bal Pharma to develop Akaal Pharma’s IP within the veterinary field.
The first veterinary indication will be against atopic dermatitis (AD) in dogs. Akaal’s ABV-119 is the first of its kind oral drug candidate for the treatment of AD in dogs. ABV-119 is a multimodal therapy that includes anti-inflammatory/ immune modulatory and anti-itch effects. AB VET plans to begin clinical development in H1 2018.
Bal Pharma is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.85 |
Dr. Reddys Lab | 1173.55 |
Cipla | 1525.50 |
Lupin | 2018.35 |
Zydus Lifesciences | 859.10 |
View more.. |